US00650F1093
US00650F1093
Adaptive Biotechnologies Corpor
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 4.23B EUR | 3.41B EUR | 2.22B EUR | 2.5B EUR |
Enterprise Value | 4.24B EUR | 3.65B EUR | 2.22B EUR | 2.51B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -146.8x | -- | -- | -- |
Price to Sales | 13.72x | 11.07x | 7.5x | 11.12x |
Price to Book | 29.5x | 23.87x | 10.25x | 11.41x |
EV/Revenue | 13.76x | 11.86x | 7.5x | 11.16x |
EV/EBITDA | -198.71x | -- | -- | -- |
Price to FCF (P/FCF) | 222.78x | -- | -- | -- |
EV/FCF | 223.32x | -- | -- | -- |
FCF Yield | 0.45% | -0.7% | -1.33% | -0.77% |